Veteran biotech investors see more than their fair share of zombies. Not the flesh-eating kind popularized on the shows like The Walking Dead, but former highflying stocks banished to obscurity after a big drug failure only to rise again without valid reason. But every once in a while, you see a company come back stronger than before it was sent into the penny-stock wilderness.
In this video, Motley Fool health-care analyst discusses how Keryx Pharmaceuticals' impressive 76% pop and how key drug Zerenex's successful trial has reinvented Keryx into more than just a zombie biotech.
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in our brand-new free report: "The Motley Fool's Top Stock for 2013." Grab a free copy for a limited time. Just click here to access the report and find out the name of this under-the-radar company.
The article Keryx: This Biotech Is No Zombie originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. Follow him on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.